MedExecWomen Empowers Women in Leadership Roles in the Medical Device Diagnostics and Digital Health Industries

MedExecWomen, an organization dedicated to empowering women in leadership roles in the medical device, diagnostics, drug delivery, and digital healthcare industries, hosted the second annual MedExecWomen conference on October 26, 2021, in Boston, MA.

The event brought together executives and thought leaders from Johnson & Johnson, Boston Scientific, Medtronic, GE Healthcare, 3M Health Information Systems, Mass General Brigham, New England Baptist, United Health Group, Tufts Medical, and the Bill & Melinda Gates Foundation. Topics discussed during the agenda covered medical innovation strategies in a post-COVID world.

Helen Routh, Board President of MedExecWomen said “Innovation in healthcare, particularly post COVID, requires us to work across industry sectors, alongside clinicians and payers. MedExecWomen does just this – sharing learnings and building networks with peers that will drive further improvements in outcomes.”

“We founded MedExecWomen to be a forum for senior leaders to network – to learn and engage with peers in the medtech world. We were so pleased to be back together after 18 months, and we look forward to our next opportunity to gather in spring/early summer of 2022,” said Laurie Halloran of Halloran Consulting Group.

Maria Shepherd of Medi-Vantage said, “We had an amazing turnout with over one hundred women attending the MedExecWomen meeting. Our speakers were leading physicians and experts from the medical device industry.”

MedExecWomen supports female executives by creating venues to network, refine leadership skills, and develop relevant expertise. The organization strives to:

  • Increase the value brought to healthcare by female executives
  • Strengthen future gender diversity through a connected, effective, and visible female leadership pool
  • Support female executives as they navigate ambiguity and complexity to lead in rapidly changing markets

MedExecWomen’s third annual conference will be held June 14, 2022, in Boston, MA.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”